

Environmental Stewardship



VIATRIS™ colleagues around the world know that human health and environmental health are closely interconnected. We are committed to doing our part to advance sustainable practices and minimize our environmental footprint while helping ensure reliable access to medicine.

Through our company-wide sustainability goals and the work we do every day, we actively manage our impact on climate change, energy use, water management and air emissions.

Climate Change Mitigation and Adaptation

As a healthcare company with a global reach, we are committed to taking action against climate change, which poses health dangers on a worldwide scale. Our work to reduce the effects of climate change helps improve the health of those we serve, build resilience in our operations and protect the communities where we live and work.

The Science Based Target Initiative (SBTi) independently assessed and approved our greenhouse gas emissions targets in line with its strict, globally recognized criteria in 2022. Science-based targets provide clearly defined pathways to reduce greenhouse gas emissions in line with the Paris Agreement goal of limiting global warming to 1.5°C preindustrial levels. Having the targets validated and approved by the SBTi provides credibility to the relevance of our targets as we continue to work to do our part to fight climate change. The SBTi classified Viatris' scope 1 and 2 target ambition and has determined that it is in line with the 1.5°C trajectory.

Key actions and strategies for making progress toward our SBTi climate targets will include:

- Increasing renewable energy usage
- Implementing energy-efficiency projects
- Preventing refrigerant leaks and transitioning to greener refrigerants
- Using alternative fuels and technologies
- Leveraging infrastructure upgrades and utility replacement projects

Our Greenhouse Gas Emissions Reduction Targets



- ▶ **Absolute scope 1 and 2 greenhouse gas emissions** by 42% by 2030 from a 2020 base year.*
- ▶ **Absolute scope 3 greenhouse gas emissions** covering purchased goods and services, capital goods, fuel- and energy-related activities, and upstream transportation and distribution by 25% by 2030 from a 2020 base year.

* *The target boundary includes land-related emissions and removals from bioenergy feedstock.*

From 2020 to 2022, Viatris reduced its scope 1 and 2 GHG emissions from 781.4 to 727 thousand metric tons CO₂e.



We have reported to the CDP climate program since 2017 and make our climate and water responses available on CDP's [public response web page](#) to better inform stakeholders.

2022 CDP Scores
 Water security **B**
 Climate change **B-**

Our Additional Environmental Goals

Our Water Goal:



- ▶ To perform water risk assessments for all 15 Viatris site locations in high or extremely high water stress areas as identified by the World Resource Institute and to identify appropriate water conservation initiatives by 2025.

Our Progress: In 2022, we performed five water risk assessments—four in our India facilities and one in Turkey.

The remaining locations are on target for completion in 2023 and 2024, keeping us on track to meet our overall goal by 2025.

Our Waste Goal:



- ▶ By 2030, increase the number of zero-waste landfill locations by 50% from a 2020 baseline.

Our Progress: We currently have 16 zero-waste landfill locations — an increase of three locations from our 2020 baseline. We have five locations with 1% or less of their waste going to a landfill and another two locations with 2% or less going to landfills. We are on track to achieve our goal of 20 zero-waste to landfill locations by 2030.

Fighting AMR via Responsible Manufacturing

As a founding member of the AMR Industry Alliance (AMRIA), we are committed to partnering across industry to collectively advance initiatives addressing AMR. These efforts have led to progress in advancing science-based approaches to help manage the impact of antimicrobial manufacturing. We have adopted the AMRIA Common Antibiotic Manufacturing Standard for our own operations and external supply chain. Viatris participated in the development of the Antibiotic Manufacturing Framework, which was then transitioned to a Standard in 2022 by the AMRIA.

All applicable Viatris manufacturing locations with antibiotic production have been assessed and are in adherence with the AMRIA Antibiotic Manufacturing Standard, including meeting the PNEC (RQ<1) as calculated by mass balance.

In our external supply chain, we are working in a phased approach to assess suppliers' management and performance on the AMRIA Antibiotic Manufacturing Standard. Suppliers that are not fully in adherence to the AMRIA Antibiotic Manufacturing Standard develop and implement corrective actions. Viatris monitors these suppliers within established mitigation plans. For the work in the external supply chain, Viatris leverages its full membership in the Pharmaceutical Supply Chain Initiative (PSCI). Using PSCI resources for supplier risk assessments and audits, 35 suppliers were assessed in 2022.



Smart Solutions to Reduce Packaging Waste

As part of our work to reduce our environmental impact while safeguarding access to high-quality medicines, we seek ways to reduce the volume and types of materials we use in packaging while complying with regulatory and quality requirements.

Our priorities are managing and protecting the safety, quality and efficacy of medicines; facilitating patients' administration of medicine; ensuring access to medicines and compliance with quality and regulatory standards. With these priorities in mind, our teams in commercial, packaging, regulatory, quality and other areas collaborate closely to reduce packaging waste where possible in our existing portfolio and pipeline.

Efforts include the elimination of outer cartons or paper leaflets on medicine bottles – subject to the acceptance of the receiving market as well as the regulatory and quality departments; using recyclable virgin polymer for bottles and caps; harmonizing pack sizes across multiple markets with multiple languages included on one pack and replacing small blister packs with large bottle packs. Today, these efforts can't be universally applied as different countries and customers have different regulations and preferences, but we work to scale solutions across more countries when appropriate.

